These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19926957)

  • 1. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
    Ouyang DW; Brogly SB; Lu M; Shapiro DE; Hershow RC; French AL; Leighty RM; Thompson B; Tuomala RE
    AIDS; 2010 Jan; 24(1):109-14. PubMed ID: 19926957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
    Ouyang DW; Shapiro DE; Lu M; Brogly SB; French AL; Leighty RM; Thompson B; Tuomala RE; Hershow RC
    AIDS; 2009 Nov; 23(18):2425-30. PubMed ID: 19617813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
    Aaron E; Kempf MC; Criniti S; Tedaldi E; Gracely E; Warriner A; Kumar R; Bachmann LH
    PLoS One; 2010 Sep; 5(9):e12617. PubMed ID: 20838641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
    Peters PJ; Polle N; Zeh C; Masaba R; Borkowf CB; Oyaro B; Omolo P; Ogindo P; Ndivo R; Angira F; Lando R; Fowler MG; Weidle PJ; Thomas TK
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):142-9. PubMed ID: 22020069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
    Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
    J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
    HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
    Bera E; Mia R
    S Afr Med J; 2012 Oct; 102(11 Pt 1):855-9. PubMed ID: 23116743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
    Edwards SG; Larbalestier N; Hay P; de Ruiter A; Welch J; Taylor GP; Easterbrook P
    HIV Med; 2001 Apr; 2(2):89-91. PubMed ID: 11737384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
    Coffie PA; Tonwe-Gold B; Tanon AK; Amani-Bosse C; Bédikou G; Abrams EJ; Dabis F; Ekouevi DK
    BMC Infect Dis; 2010 Jun; 10():188. PubMed ID: 20576111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious toxicity associated with continuous nevirapine-based HAART in pregnancy.
    van Schalkwyk JE; Alimenti A; Khoo D; Maan E; Forbes JC; Burdge DR; Gilgoff S; Money DM
    BJOG; 2008 Sep; 115(10):1297-302. PubMed ID: 18715416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
    McKoy JM; Bennett CL; Scheetz MH; Differding V; Chandler KL; Scarsi KK; Yarnold PR; Sutton S; Palella F; Johnson S; Obadina E; Raisch DW; Parada JP
    Drug Saf; 2009; 32(2):147-58. PubMed ID: 19236121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
    Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012.
    Dube N; Adewusi E; Summers R
    S Afr Med J; 2013 May; 103(5):322-5. PubMed ID: 23971123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nelfinavir and nevirapine side effects during pregnancy.
    Timmermans S; Tempelman C; Godfried MH; Nellen J; Dieleman J; Sprenger H; Schneider ME; de Wolf F; Boer K; van der Ende ME;
    AIDS; 2005 May; 19(8):795-9. PubMed ID: 15867493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
    Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
    João EC; Calvet GA; Menezes JA; D'Ippolito MM; Cruz ML; Salgado LA; Matos HJ
    Am J Obstet Gynecol; 2006 Jan; 194(1):199-202. PubMed ID: 16389032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.